Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| DK083554 | Other Identifier | NIDDK |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims.
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| hyperglycemic clamp-Meal tolerance test | Experimental | these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls |
|
| Labeled meal tolerance test | Experimental | The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| exendin-(9-39) | Drug | hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion |
|
| Measure | Description | Time Frame |
|---|---|---|
| The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculated | up to 1 year (10 sessions) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marzieh Salehi, MD MS | Contact | 210-567-6691 | salehi@uthscsa.edu | |
| Jennifer Foster, MSN | Contact | 210-450-8696 | fosterj6@uthscsa.edu |
| Name | Affiliation | Role |
|---|---|---|
| Marzieh Salehi, MD,MS | Marzieh Salehi | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Texas Diabetes Institute - University Health System | Recruiting | San Antonio | Texas | 78207 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24315990 | Derived | Salehi M, Gastaldelli A, D'Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology. 2014 Mar;146(3):669-680.e2. doi: 10.1053/j.gastro.2013.11.044. Epub 2013 Dec 4. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007003 | Hypoglycemia |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C083773 | exendin (9-39) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| exendin -(9-39) | Drug | 2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics. |
|
|
| South Texas Veterans Health Care System | Recruiting | San Antonio | Texas | 78229 | United States |
|